8-K: Recursion Pharmaceuticals Secures Additional Shareholder Support for Exscientia Acquisition

Recursion Pharmaceuticals has obtained an irrevocable undertaking from Evotec SE, further solidifying support for its acquisition of Exscientia.

Summary

• Recursion Pharmaceuticals is in the process of acquiring Exscientia through a scheme of arrangement.
• Evotec SE, holding approximately 11% of Exscientia's shares, has agreed to vote in favor of the acquisition.
• This agreement brings the total support for the acquisition to approximately 53% of Exscientia's outstanding share capital.
• The acquisition is subject to shareholder approvals and other conditions.
• A joint proxy statement will be filed with the SEC providing full details of the proposed transaction.

Sentiment

Score: 8

Explanation: The document indicates positive progress in the acquisition process with increased shareholder support, suggesting a favorable outlook for the transaction.

Positives

• Increased shareholder support for the acquisition of Exscientia.
• The irrevocable undertaking from Evotec SE significantly increases the likelihood of the acquisition being approved.
• The transaction is progressing as planned with key shareholder support secured.

Risks

• The acquisition is still subject to shareholder approvals and regulatory clearances.
• There is a risk that the transaction agreement could be terminated.
• The integration of Exscientia's business with Recursion's may present challenges.
• Legal proceedings could arise related to the acquisition.
• Economic, market, or business conditions could impact the combined company's operations.

Future Outlook

The document outlines the proposed combination of Recursion and Exscientia, with the goal of delivering better treatments to patients faster and at a lower cost. The success of the acquisition is dependent on shareholder approvals and regulatory clearances.

Industry Context

This acquisition is part of a trend in the pharmaceutical industry where companies are combining to leverage technology and data to accelerate drug discovery and development. The combination of Recursion's AI-driven platform with Exscientia's drug discovery capabilities could create a more efficient and effective drug development process.

Comparison to Industry Standards

• The acquisition of Exscientia by Recursion is similar to other mergers in the biotech industry where companies are seeking to combine their strengths in AI and drug discovery.
• Other companies such as Schrodinger and Relay Therapeutics are also using computational methods for drug discovery, but the specific combination of Recursion's platform and Exscientia's capabilities is unique.
• The success of this acquisition will be measured against the ability of the combined company to accelerate drug development and bring new treatments to market faster than competitors.

Stakeholder Impact

• Shareholders of both Recursion and Exscientia will be impacted by the proposed acquisition.
• Employees of both companies may experience changes as a result of the merger.
• Customers and partners of both companies may see changes in the products and services offered.

Next Steps

• File a joint proxy statement with the SEC.
• Obtain shareholder approvals from both Recursion and Exscientia.
• Secure regulatory approvals.
• Complete the scheme of arrangement under UK law.

Key Dates

Keywords

Acquisition, Recursion Pharmaceuticals, Exscientia, Irrevocable Undertaking, Shareholder Approval, Scheme of Arrangement, Merger, Evotec SE